Latest News
Category: Clinical
Telix has secured an exclusive Intellectual Property licence agreement with the German Cancer Research Center (DKFZ) for a novel imaging technology in the field of image-guided surgery for prostate...
Read more
Telix Pharmaceuticals Japan K.K. is pleased to announce the completion of Phase I enrolment of the Company’s Phase I/II ZIRDAC-JP study of Telix’s renal cancer diagnostic imaging product TLX250-CDx (89Zr-girentuximab)...
Read more
Telix and Eczacıbaşı-Monrol Nuclear Products Co. are pleased to announce that the first patients have been dosed in Telix’s Phase III ZIRCON clinical...
Read more
Telix announces first two patients dosed in phase I trial of lung & ovarian cancer...
Read more
Telix announces the first patient has been dosed in a Phase I/II study of Telix’s renal cancer diagnostic imaging product TLX250-CDx in...
Read more
Telix Pharmaceuticals Limited announces that the FDA has provided feedback that will enable the Company to finalize the Phase 3 PROSTACT...
Read more
Telix Pharmaceuticals Limited announces that the Company’s ZIRCON phase III trial of TLX250-CDx has recommenced patient recruitment in...
Read more
Telix Pharmaceuticals Limited is pleased to announce that the FDA has approved the ZIRCON study for American...
Read more
Telix Pharmaceuticals announces that it has submitted a complete clinical briefing package to the US FDA for its first product...
Read more
Telix Pharmaceuticals Limited announces that it has submitted a Phase 3 IND application to the FDA for...
Read more